nitrophenide: Structure in first source
ID Source | ID |
---|---|
PubMed CID | 10842 |
CHEMBL ID | 1721015 |
SCHEMBL ID | 288227 |
MeSH ID | M0284562 |
Synonym |
---|
nsc 655043 |
bis(3-nitrophenyl) disulphide |
4oj0bva4vq , |
nsc 42172 |
nsc 66160 |
unii-4oj0bva4vq |
megasul (van) |
einecs 208-677-6 |
disulfide, bis(m-nitrophenyl) |
disulfide, bis(3-nitrophenyl) |
m,m'-dinitrodiphenyl disulfide |
megasul |
3,3'-dinitrodiphenyl disulfide |
bis(m-nitrophenyl) disulfide |
mls002608369 , |
hinagen |
nitrophenide |
nsc-42172 |
nsc42172 |
537-91-7 |
bis(3-nitrophenyl) disulfide |
hydroxy(3-((3-(hydroxy(oxido)amino)phenyl)dithio)phenyl)azane oxide |
nsc655043 |
nsc-655043 |
nsc-66160 |
nsc66160 |
1-nitro-3-[(3-nitrophenyl)disulfanyl]benzene |
disulfide, bis(diethylthio-carbamoyl) |
AC-11157 |
B2929 |
3-nitrophenyl disulfide |
1-nitro-3-(3-nitrophenyl)disulfanylbenzene |
odofdwdussfumn-uhfffaoysa- |
inchi=1/c12h8n2o4s2/c15-13(16)9-3-1-5-11(7-9)19-20-12-6-2-4-10(8-12)14(17)18/h1-8h |
smr001527118 |
AKOS001044134 |
HMS3085E07 |
A829773 |
1-nitro-3-[(3-nitrophenyl)dithio]benzene |
FT-0614085 |
SCHEMBL288227 |
bis-(3-nitrophenyl)disulfide |
3-nitrophenyldisulphide |
3-nitrophenyl disulphide |
bis-(3-nitrophenyl)-disulfide |
bis(m-nitrophenyl)disulfide |
bis(3-nitrophenyl)disulfide |
nitrophenide [mi] |
DTXSID1060219 |
mfcd00007246 |
W-105709 |
CHEMBL1721015 |
bdbm81213 |
cid_10842 |
1-nitro-3-[(3-nitrophenyl)disulfanyl]benzene # |
sr-01000872609 |
SR-01000872609-2 |
1,2-bis(3-nitrophenyl)disulfane |
Z56899184 |
AMY21925 |
EN300-17249 |
D78361 |
bis-(3-nitrophenyl) disulfide |
Q27260292 |
3,3`-dinitrodiphenyl disulfide bis(3-nitrophenyl)disulfide |
3,3'-dinitrodiphenyl disulphide |
AKOS040744768 |
Excerpt | Reference | Relevance |
---|---|---|
"Nitrophenide treatment did not affect parasite asexual reproduction, suggesting specificity for the sexual stage of the life cycle." | ( Nitrophenide (Megasul) blocks Eimeria tenella development by inhibiting the mannitol cycle enzyme mannitol-1-phosphate dehydrogenase. Allocco, JJ; Feiglin, M; Myers, RW; Nare, B; Profous-Juchelka, H; Schmatz, DM, 2001) | 2.47 |
Pathway | Proteins | Compounds |
---|---|---|
mannitol cycle | 3 | 15 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 10.0000 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Nrf2 | Homo sapiens (human) | Potency | 19.9526 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 8.9125 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
TDP1 protein | Homo sapiens (human) | Potency | 4.1367 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 22.3872 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 12.5893 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 11.2202 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
67.9K protein | Vaccinia virus | Potency | 8.9125 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 3.9811 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.3769 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 28.1838 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 23.7246 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 5.6234 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Alpha-synuclein | Homo sapiens (human) | Potency | 3.9811 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.1623 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 (µMol) | 41.4900 | 0.8890 | 21.0286 | 71.5000 | AID504765; AID540252; AID540269 |
glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 8.8700 | 12.8518 | 17.8000 | AID504792 |
rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 53.9200 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
hypothetical protein SA1422 | Staphylococcus aureus subsp. aureus N315 | IC50 (µMol) | 2.6750 | 1.6200 | 20.9350 | 62.7000 | AID624317; AID651709 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 4.2540 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 4.6250 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (33.33) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |